Study of Durvalumab With Tremelimumab Versus SoC as 1st Line Therapy in Metastatic Non Small-Cell Lung Cancer (NSCLC) (NEPTUNE)
Clinical trial NCT02542293 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT02542293
- Sponsor
- AstraZeneca
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2015-11-03
- Primary completion
- 2020-09-21
- Enrollment
- 953
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.